SYNDROMIC TESTING

QIAsphere Insights

Your compass for disease incidence and prevalence


Confidently navigate the ebb and flow of infectious diseases in your community – and beyond – with QIAsphere Insights. With data from your own QIAstat-Dx instruments and de-identified data from instruments around the world, track everything from pathogen diversity, to rates of co-detection, to Ct value measures. With QIAsphere Insights, the power of clinical epidemiology is in your hands.
Could you be underdiagnosing respiratory infections?
If you're solely relying on low-plex testing, our data suggests you could be missing crucial information. Download our recent study to learn more.
Get the poster

What does QIAsphere Insights offer?

How can QIAsphere Insights support my work?

Useful findings from the Insights dashboard

Low-plex doesn’t cut it for respiratory infections


Our Insights dashboard shows that if you only test your patients for a few viral respiratory pathogens (Influenza A, Influenza B, RSV and SARS-CoV-2), you could be missing a huge proportion of positive cases.

A tale of two (types of) pathogens


The Centers for Disease Control and Prevention estimates that up to 50% of all outpatient antibiotic use may be unnecessary or inappropriate in selection, dose and duration (https://www.cdc.gov/antibiotic-use/data/outpatient-prescribing/index.html).

This rings true with results from our Insights dashboard for respiratory infections. In 2022, bacteria accounted for a very small percentage of positive detections, with viruses making up the vast majority.

Get even more insight with our app

Found an unexpected result in your testing and need a quick refresher on pathogen biology? Find answers fast with the Pathogen Guide, our new medical reference app. Quickly access reliable clinical information about dozens of viruses, bacteria, fungi and parasites.

Get the app

More to explore

Data is aggregated from QIAsphere-connected QIAstat-Dx instruments only. Not all QIAstat-Dx instruments are connected to QIAsphere.

Access to the QIAsphere Insights dashboard requires a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.

Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor.

The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner